Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 269

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Open access
Wang, Yifan, Bernhardy, Andrea J., Cruz, Cristina, Krais, John J., Nacson, Joseph, Nicolas, Emmanuelle, Peri, Suraj, van der Gulden, Hanneke, van der Heijden, Ingrid, O'Brien, Shane W., Zhang, Yong, Harrell, Maribel I., Johnson, Shawn F., Candido Dos Reis, Francisco J., Pharoah, Paul D. P., Karlan, Beth, Gourley, Charlie, Lambrechts, Diether, Chenevix-Trench, Georgia, Olsson, Håkan, Benitez, Javier J., Greene, Mark H., Gore, Martin, Nussbaum, Robert, Sadetzki, Siegal, Gayther, Simon A., Kjaer, Susanne K., kConFab Investigators, D'Andrea, Alan D., Shapiro, Geoffrey I., Wiest, David L., Connolly, Denise C., Daly, Mary B., Swisher, Elizabeth M., Bouwman, Peter, Jonkers, Jos, Balmaña, Judith, Serra, Violeta, Johnson, Neil·2016·Cancer Research

Abstract

Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact. In this study, we investigated the impact of mutations on BRCA1 isoform expression and therapeutic response. Cancer cell lines and tumors harboring mutations in exon 11 of BRCA1 express a BRCA1-Δ11q splice variant lacking the majority of exon 11. The introduction of frameshift mutations to exon 11 resulted in nonsense-mediated mRNA decay of full-length, but not the BRCA1-Δ11q isoform. CRISPR/Cas9 gene editing as well as overexpression experiments revealed that the BRCA1-Δ11q protein was capable of promoting partial PARPi and cisplatin resistance relative to full-length BRCA1, both in vitro and in vivo. Furthermore, spliceosome inhibitors reduced BRCA1-Δ11q levels and sensitized cells carrying exon 11 mutations to PARPi treatment. Taken together, our results provided evidence that cancer cells employ a strategy to remove deleterious germline BRCA1 mutations through alternative mRNA splicing, giving rise to isoforms that retain residual activity and contribute to therapeutic resistance. Cancer Res; 76(9); 2778–90. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-0186

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 269

Metadata

Authors
Wang, Y., Bernhardy, A. J., Cruz, C., Krais, J. J., Nacson, J., Nicolas, E., Peri, S., van der Gulden, H., van der Heijden, I., O'Brien, S. W., Zhang, Y., Harrell, M. I., Johnson, S. F., Candido Dos Reis, F. J., Pharoah, P. D. P., Karlan, B., Gourley, C., Lambrechts, D., Chenevix-Trench, G., Olsson, H., Benitez, J. J., Greene, M. H., Gore, M., Nussbaum, R., Sadetzki, S., Gayther, S. A., Kjaer, S. K., kConFab Investigators, D'Andrea, A. D., Shapiro, G. I., Wiest, D. L., Connolly, D. C., Daly, M. B., Swisher, E. M., Bouwman, P., Jonkers, J., Balmaña, J., Serra, V., & Johnson, N.
Venue
Cancer Research
Published
2016-05-01
Volume
76
Issue
9
Pages
2778-2790
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2343436177
Cited by
269
References
49
FWCI
9.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-0186
The paper
Wang, Y., Bernhardy, A. J., Cruz, C., Krais, J. J., Nacson, J., Nicolas, E., Peri, S., van der Gulden, H., van der Heijden, I., O'Brien, S. W., Zhang, Y., Harrell, M. I., Johnson, S. F., Candido Dos Reis, F. J., Pharoah, P. D. P., Karlan, B., Gourley, C., Lambrechts, D., Chenevix-Trench, G., . . . Johnson, N. (2016). The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-0186

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.